News
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...
Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results